Global Targeted Drug Delivery Partnering 2010-2015

NEW YORK, Jan. 26, 2016 /PRNewswire/ -- Provides understanding and access to the targated drug delivery partnering deals and agreements entered into by the worlds leading healthcare companies.

Targeted Drug Delivery Partnering 2010-2015 report provides understanding and access to the targeted drug delivery partnering deals and agreements entered into by the world's leading healthcare companies.
Trends in targeted drug delivery partnering deals
Top targeted drug delivery deals by value
Deals listed by company A-Z, deal type, stage of development, therapy type

Targeted Drug Delivery Partnering 2010-2015 provides understanding and access to the targeted drug delivery partnering deals and agreements entered into by the world's leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter targeted drug delivery partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors drug delivery technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This report contains over 150 links to online copies of actual targeted drug delivery deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

The initial chapters of this report provide an orientation of targeted drug delivery dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in targeted drug delivery dealmaking since 2010

Chapter 3 is the most popular chapter that includes details of average headline, upfront, milestone and royalty terms.

Chapter 4 provides a review of the leading targeted drug delivery deals since 2010. Deals are listed by headline value, most active of all biopharma companies and signed by big pharma. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides a comprehensive directory of targeted drug delivery partnering deals signed and announced since 2010. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and therapy type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in targeted drug delivery partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about targeted drug delivery partnering in the research, development and commercialization of drug delivery technologies and products.

Report scope

Targeted Drug Delivery Partnering 2010-2015 is intended to provide the reader with an in-depth understanding and access to targeted drug delivery trends and structure of deals entered into by leading companies worldwide.

This data driven report includes:

Trends in targeted drug delivery dealmaking in the biopharma industry since 2010
Access to summary headline, upfront, milestone and royalty data
Access to over 150 targeted drug delivery actual deal records
The leading targeted deals by value since 2010

In Targeted Drug Delivery Partnering 2010-2015, the available deals are listed by:

Headline value
Upfront payment value
Royalty rate value
Company A-Z
Industry sector
Stage of development at signing
Deal component type
Therapy type

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Targeted Drug Delivery Partnering 2010-2015 provides the reader with the following key benefits:

In-depth understanding of targeted drug delivery deal trends since 2010
Access to summary headline, upfront, milestone and royalty data
Comprehensive access to over 150 actual deal records entered into by the world's biopharma companies since 2010
Insight into key deal terms included in contracts, where disclosed
Understand the key deal terms companies have agreed in deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Read the full report: http://www.reportlinker.com/p03158258-summary/view-report.html

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

http://www.reportlinker.com


__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker

Related Links

http://www.reportlinker.com